NanoViricides' NV-387 Broad-Spectrum Antiviral Showcases Promise in Combatting Rising Measles Cases Worldwide.

NanoViricides, a clinical-stage company, is developing NV-387, a broad-spectrum antiviral drug candidate, to combat increasing measles cases worldwide. NV-387 has shown effectiveness and safety in animal studies and completed a Phase I clinical trial with no adverse events. The company plans to explore orphan drug designation and fast track designation for the NV-387 Measles indication, which could accelerate its approval. Measles is a rare disease with severe morbidity, high transmission rates, and the potential to wipe out previously learned immunity.

NanoViricides, Inc. (NASDAQ:NNVC), a clinical-stage biopharmaceutical company, has announced its drug candidate NV-387 as a potential solution to the growing global measles epidemic. The company, which specializes in broad-spectrum antivirals based on host-mimetic nanomedicine technology, is targeting the increasing measles cases worldwide, particularly in industrialized nations like the USA, Canada, UK, and European Union [1].

NV-387 has demonstrated effectiveness and safety in animal model studies using humanized h-CD150+ knock-in mice. The drug candidate has completed a Phase I clinical trial with no reported adverse events, indicating excellent safety and tolerability in humans. NanoViricides is now exploring orphan drug designation and fast track designation for NV-387, which could significantly expedite its approval process [1].

Measles is a rare orphan disease in the USA, characterized by severe morbidity, high transmission rates, and the potential to wipe out previously learned immunity. The disease affects mostly children and has seen a resurgence in recent years, with over 1,300 confirmed cases reported in the USA as of July 22, 2025, breaking the 2019 record of 1,274 cases [1]. Hospitalization rates for measles in the USA are about 13%, and fatalities are rare, although there have been three deaths reported in 2025 [1]. Canada is experiencing a much worse measles season, with more than 3,800 cases to date in 2025 [1]. The UK has also issued a measles holiday warning this year, with England alone reporting more than 3,000 cases in 2024 [1]. Globally, there have been about 108,000 confirmed measles cases in 2025 to date, compared to about 360,000 in 2024 [1].

The sustained measles vaccination rate of at least 95% is estimated to be required to maintain community immunity. However, growing vaccine hesitancy, immune dysfunction, obesity, and diabetes are contributing to the fall in measles vaccination rates, making it increasingly difficult to achieve herd immunity even in developed countries [1].

NanoViricides' NV-387 offers a promising alternative to vaccines for controlling measles. If approved, it could significantly impact the global measles landscape, providing a much-needed treatment option for patients and helping to curb the spread of the disease. The company's focus on advancing NV-387 into Phase II human clinical trials underscores its commitment to addressing this critical medical need.

References:
[1] NanoViricides, Inc. (2025). Press Release. Retrieved from [http://www.webdisclosure.com/press-release/measles-cases-increasing-worldwide-need-the-new-nv-387-broad-spectrum-antiviral-to-combat-says-nanoviricides-dwnjfipgrxe](http://www.webdisclosure.com/press-release/measles-cases-increasing-worldwide-need-the-new-nv-387-broad-spectrum-antiviral-to-combat-says-nanoviricides-dwnjfipgrxe)